50 results about "Liver ischemia" patented technology

The invention discloses application of LECT2 as a diagnosis and treatment target of hepatic ischemia reperfusion injury. According to the present invention, the Print method operation patient sample is detected to discover that the expression of the LECT2 in the hepatic ischemia reperfusion injury is up-regulated; on the basis, a liver ischemia reperfusion injury model is constructed by knocking out a mouse through the LECT2 gene, and a result shows that the liver ischemia reperfusion injury of the mouse is obviously reduced by knocking out the LECT2 gene and transferring the LECT2-shRNA into the LECT2 gene, and the liver ischemia reperfusion injury of the mouse is aggravated by LECT2 recombinant protein; it is shown that inhibition of expression of LECT2 is beneficial to improvement or treatment of hepatic ischemia injury; furthermore, the invention further finds that liver injury can be relieved by inhibiting the combination of LECT2 and Tie1; the LECT2 / Tie1 signal channel can also be used as a target spot for treating the liver ischemia reperfusion injury.

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

The present invention discloses an amlodipine drug targeted delivery system and a preparation method thereof. The targeted delivery system can improve the targeting of amlodipine in preventing liver ischemia-reperfusion injury, and the preparation method is simple, with high feasibility and strong practicality. The amlodipine drug targeted delivery system (Am@EXOs) prepared by the present invention enables amlodipine to be distributed in the liver of a mouse model of liver ischemia-reperfusion injury, and achieves precise inhibition of calcium ion overload in liver cells with a minimum dose of amlodipine, thereby reducing cell damage, improving the targeting of amlodipine in preventing liver ischemia-reperfusion injury, and reducing the use cost of amlodipine.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of a transcription factor ZHX2 in diagnosis and treatment of hepatic ischemia-reperfusion injury. Specifically, research finds that the expression of ZHX2 after ischemia reperfusion injury is reduced, and HIRI cell necrosis and generation and development of HIRI are obviously promoted by specifically knocking out Zhx2 from liver cells, which are further proved in marginal liver IRI, while the ZHX2 has a protective effect on marginal fatty liver ischemia reperfusion injury. In conclusion, the ZHX2 can be used as a biological marker and a related treatment target of the hepatic ischemia reperfusion injury, especially marginal hepatic ischemia reperfusion injury, so that the ZHX2 has good clinical application value and social benefit.

The invention relates to the technical field of medicines, in particular to application of mulberry bark extract in preparation of medicines for preventing and / or treating ischemia-reperfusion injury, and finds that morusin administration treatment can effectively relieve pathological injury of mouse liver tissue, reduce activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum after hepatic ischemia-reperfusion, and can be used for preparing medicines for preventing and / or treating ischemia-reperfusion injury. The expression of inflammatory cytokines is inhibited, and the proportion of apoptotic cells is remarkably reduced. The invention further finds that the morusin inhibits the expression of 15-hydroxyeicosapentaenoic acid (15-HETE), and the protection effect of the morusin on the HIRI can be reversed by adding the 15-HETE, so that the morusin can be used for inhibiting the expression of the 15-hydroxyeicosapentaenoic acid (15-HETE).

The invention discloses an application of gentiopicroside in preparation of a medicine for protecting liver ischemia-reperfusion injury, discusses the protection effect of gentiopicroside on mouse liver ischemia-reperfusion injury, and preliminarily reveals a ferroptosis related molecular mechanism. The invention discloses that gentiopicroside can play a role in protecting HIRI by inhibiting ferroptosis, oxidative stress and inflammatory response, further indicates that gentiopicroside can be further used for preparing a medicine for protecting liver ischemia-reperfusion injury, and meanwhile, the invention discloses the effect of ferroptosis in HIRI, discovers a new therapeutic target, and has a good application prospect. A new thought and a new direction are provided for treatment of liver diseases.

The invention relates to application of a lysine methyltransferase DOT1L inhibitor in preparation of a medicine for treating hepatic ischemia reperfusion injury, and belongs to the technical field of biological medicine. The lysine methyltransferase DOT1L inhibitor is SGC0946, and the lysine methyltransferase DOT1L inhibitor is The invention discloses a lysine methyltransferase DOT1L inhibitor for the first time, and particularly discloses new application of SGC0946 in preparation of a medicine for treating liver ischemia reperfusion injury. The invention proves that the expression level of the DOT1L in a mouse suffering from the hepatic ischemia reperfusion injury is obviously improved, so that the methylation level of H3K79 is obviously increased, the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase are obviously increased, and ferroptosis marker genes Ptgs2 and Cac1 are obviously increased, which indicates that the DOT1L can be used as a target spot for treating the hepatic ischemia reperfusion injury and can be used for treating the hepatic ischemia reperfusion injury. The lysine methyltransferase DOT1L inhibitor can be used for preparing the medicine for treating the hepatic ischemia reperfusion injury.

The present invention relates to the use of a lysine methyltransferase DOT1L inhibitor in the preparation of a medicament for treating liver ischemia-reperfusion injury, belonging to the technical field of biomedicine. The lysine methyltransferase DOT1L inhibitor is SGC0946. The present invention discloses for the first time the new use of a lysine methyltransferase DOT1L inhibitor, especially SGC0946, in the preparation of a medicament for treating liver ischemia-reperfusion injury. The present invention confirms that the expression level of DOT1L in mice with liver ischemia-reperfusion injury is significantly increased, which in turn leads to a significant up-regulation of the H3K79 methylation level, a significant increase in the levels of alanine aminotransferase and aspartate aminotransferase, and the ferroptosis marker genes Ptgs2 and Chac1 are significantly up-regulated, indicating that DOT1L can be used as a target for treating liver ischemia-reperfusion injury, and a lysine methyltransferase DOT1L inhibitor can be used to prepare a medicament for treating liver ischemia-reperfusion injury.

The invention belongs to the technical field of pharmaceutical compounds, and particularly relates to an azaphenanthrone derivative with anti-hepatic ischemia-reperfusion injury activity as well as a preparation method and application of the azaphenanthrone derivative. The structural formula of the azaphenanthrone derivative is shown as a formula A, in the formula A, R1 is CHO or COOH, and R2 is H or Cl. According to the application, the azaphenanthrone derivative is extracted from an acupoint shell fungus fermentation solution, and experiments prove that the compound has the activity of resisting the hepatic ischemia-reperfusion injury, so that the compound has the potential to be developed into an active medicine for resisting the hepatic ischemia-reperfusion injury. And a new choice is provided for developing an active medicine for resisting the hepatic ischemia-reperfusion injury.

The invention discloses a traditional Chinese and western medicine disease and syndrome combined hepatic ischemia-reperfusion injury ligand and receptor interaction communication network construction method, system and device, a medium and a product, and relates to the field of medicine. Traditional Chinese medicinal materials related to occurrence and development of the hepatic ischemia-reperfusion injury are identified from Chinese literatures and Chinese patents; constructing a traditional Chinese medicine target group based on traditional Chinese medicines; keywords are set based on pathological knowledge of western medicine, and biomarkers or target protein groups related to occurrence and development of hepatic ischemia-reperfusion injury are identified from different literatures; constructing a disease target group based on the biomarker or the target protein group; the traditional Chinese medicine target group and the disease target group form a liver transplantation HIRI target network; and performing network topology comparison on the traditional Chinese medicine target group and the disease target group to determine an optimal traditional Chinese medicine. According to the application, the advantages of combination of traditional Chinese medicine and western medicine are exerted, and the corresponding traditional Chinese medicinal materials are determined by constructing the liver transplantation HIRI target network.

The invention discloses application of a CGAS-STING signal channel inhibitor in preparation of a medicine for preventing and treating hepatic ischemia-reperfusion injury, and relates to the technical field of biological medicine. According to the application, a cGAS-STING signal channel in macrophages is inhibited by using a cGAS inhibitor or an STING inhibitor, activation of double-stranded deoxyribonucleic acid released by a neutrophile granulocyte extracellular trapping net on a DNA induction channel is blocked, and the M1 type polarization level of the macrophages is reduced. The traditional Chinese medicine composition can effectively relieve liver inflammatory response and cell apoptosis, and a new path is provided for preventing and treating acute liver injury after liver transplantation or liver resection.

The invention relates to an application of a multifunctional supramolecular nano-platform drug, in particular to an application of a multifunctional supramolecular nano-platform in preparation of a drug for treating liver ischemia reperfusion injury. The multifunctional supramolecular nano platform is a GalAC4A supramolecular carrier loaded with naringenin NAR. The multifunctional supramolecular nano platform is prepared from naringenin NAR, galactose Gal and CAC4A in azo calixarene. The multifunctional supramolecular nano platform is a nano compound of NAR (at) GalAC4A. The multifunctional supramolecular nano platform realizes specific targeting of hepatocytes through endocytosis mediated by an asialoglycoprotein receptor. The invention provides a novel'receptor recognition-hypoxia response-collaborative treatment ', a three-party design strategy is provided, a GalAC4A supermolecular carrier loaded with naringenin (NAR) is successfully constructed, and the NAR-coated GalAC4A nano-composite is formed.

This invention belongs to the field of pharmaceutical compound technology, specifically relating to an azafibrone derivative with anti-hepatic ischemia-reperfusion injury activity, its preparation method, and its application. The structural formula of the azafibrone derivative is shown in Formula A: Among them, R 1 For CHO or COOH, R 2 The derivative is H or Cl. This application describes the extraction of an azafibrone derivative from the fermentation broth of *Cryptocaryas* fungi. Experiments have confirmed that this compound possesses anti-hepatic ischemia-reperfusion injury activity, indicating its potential to be developed into an anti-hepatic ischemia-reperfusion injury drug, providing a new option for the development of such drugs.

The invention relates to the technical field of biology, in particular to a method for intervening metabolism reprogramming of macrophages and application of the method. The invention provides a method for intervening metabolic reprogramming and inflammatory activation of macrophages, namely, by down-regulating the TRAF2 expression level of the macrophages, influencing the metabolic reprogramming of the macrophages and reducing the activation of an NLRP3 inflammatory small body pathway of the macrophages and the generation of inflammatory cytokines, the acute hepatic failure induced by LPS / D-GalN is relieved. Interference on metabolism reprogramming and inflammatory activation of macrophages based on the method is expected to be applied to intervention of other liver injuries related to macrophage homeostasis imbalance, including liver ischemia reperfusion injury, alcoholic liver injury, metabolic liver injury, autoimmune liver injury, hepatic failure and the like.

The invention discloses an application of S100A9 in treatment of lung injury caused by liver ischemia reperfusion. A liver ischemia reperfusion animal model is utilized to find that S100A9 is closely related to lung injury caused by liver ischemia reperfusion. Lung injury caused by liver ischemia reperfusion can be effectively relieved by knocking out the S100A9 gene or inhibiting a downstream signal channel mediated by the S100A9. In addition, it is also found that the S100A9 expression level has very strong correlation with lung injury after liver transplantation by collecting patients clinically subjected to liver transplantation. Research results of the invention show that S100A9 is a diagnosis and treatment marker for lung injury caused by hepatic ischemia reperfusion.

The present invention discloses an application of a PAI-1 inhibitor in the preparation of a drug for treating liver ischemia-reperfusion injury, and relates to the field of biomedicine technology. The present invention selects PAI-1 gene knockout mice and C57BL / 6 wild-type mice as experimental subjects, constructs mouse liver ischemia-reperfusion injury models respectively, and studies the function of PAI-1 in liver ischemia-reperfusion injury. The study found that after PAI-1 knockout, it can reduce liver ischemia-reperfusion injury by affecting the formation and recruitment of liver neutrophil induction network, inhibiting the inflammatory response of the liver. PAI-1 is a key gene that affects neutrophil activation and is an important target for regulating inflammatory response during the reperfusion period. Animal experiments have verified that the PAI-1 specific inhibitor PAI-039 can reduce the degree of injury of mouse liver ischemia-reperfusion, providing new ideas for the development of new drugs for preventing, alleviating and / or treating tissue ischemia-reperfusion injury.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

The present invention proposes the use of a bile acid derivative in the preparation of a drug for preventing and treating liver ischemia-reperfusion injury. The bile acid derivative is glycine-β-muricholic acid, which mediates the inflammation-inhibiting effect in liver ischemia-reperfusion injury through glycine-β-muricholic acid, and confirms its molecular mechanism of inhibiting macrophage pyroptosis, providing a new therapeutic target and strategy for the clinical prevention and alleviation of liver ischemia-reperfusion injury.

The invention belongs to the technical field of pharmaceutical compounds, and particularly relates to a steroid compound derived from blue-like bacteria fungi as well as a preparation method and application of the steroid compound. The structural formula of the steroid compound is shown as a formula A. The brand-new steroid compound is extracted from fermentation liquor of blue-like fungi, and experiments prove that the compound has the activity of resisting the hepatic ischemia-reperfusion injury, so that the compound has the potential to be developed into an active medicine for resisting the hepatic ischemia-reperfusion injury. And a new choice is provided for developing an active medicine for resisting the hepatic ischemia-reperfusion injury.

The present invention discloses a nanoformulation for protecting against liver ischemia-reperfusion injury and its application. The nanoformulation comprises glucose-6-phosphate disodium, an esterase-responsive charge-reversal polymer (ERP), a lipid, and DSPE-PEG-Gal. The esterase-responsive charge-reversal polymer (ERP) serves as a nanocarrier to encapsulate glucose-6-phosphate disodium to form ERP / G6P. The lipid encapsulates ERP / G6P to form a spherical core-shell structure of Lipids / ERP / G6P. DSPE-PEG-Gal assembles with Lipids / ERP / G6P to form a PEG-Lipids / ERP / G6P nanoformulation. The present invention utilizes nanoscale size effects and active targeting to enrich G6P in the liver, improving its stability and bioavailability. The polymer ERP used can be hydrolyzed by esterases, thus exhibiting good biosafety.

The invention discloses a multi-channel nanoprobe, a preparation method thereof and application of the multi-channel nanoprobe in detection of liver ischemia reperfusion injury biomarkers, and belongs to the technical field of in-situ detection and nanoprobe preparation. The nanoprobe is a functionalized metal organic framework nanomaterial which is loaded with gold nanoparticles and a fluorescent dye in sequence and is coated with a hyaluronic acid film; the metal organic framework is prepared by taking 2-methylimidazole and zinc nitrate as raw materials; raman active molecule cytochrome C is modified by the gold nanoparticles through an amidation reaction. The preparation process is simple, the cost is low, the operation is easy, the prepared multi-channel nanoprobe has high sensitivity and excellent biocompatibility, fluorescence and SERS dual-channel simultaneous detection of ATP and O2 <.-> biomarkers in the liver cell injury process can be achieved, and the application prospect is wide. The method can be used for clinically, accurately, efficiently and quickly diagnosing the liver ischemia reperfusion injury and monitoring the disease course in real time.

The invention discloses an application of hsacirc0003258 in the prevention and / or treatment of liver ischemia reperfusion injury. According to the application disclosed by the invention, through detection, the expression of hsacirc0003258 in a liver ischemia reperfusion patient is obviously reduced; the overexpressed hsacirc0003258 constructed by using the lentiviral vector can significantly inhibit macrophage inflammation and the apoptosis level of liver cells after hypoxia and reoxygenation treatment, and improve the functions of the liver cells; the hsacirc0003258 plays a protective role in relieving the hepatic ischemia reperfusion injury, and has the potential to become a medicine for treating the hepatic ischemia reperfusion injury.

The invention relates to the technical field of medical materials, in particular to polyethylene glycol modified bovine serum albumin doped polydopamine-selenium nanoparticles as well as a preparation method and application thereof. The nano-particle comprises a nano-selenium core and a bovine serum albumin doped polydopamine shell, the diameter of the nano-particle is about 74nm, the dispersity is good, and the preparation method is simple in process. The doping of bovine serum albumin and the modification of polyethylene glycol effectively improve the dispersibility and physiological stability of the nanoparticles. The polyethylene glycol modified bovine serum albumin doped polydopamine-selenium nanoparticles prepared by the invention have good biocompatibility and good dispersibility, can quickly and efficiently remove active oxygen, and provide a new choice for treatment of hepatic ischemia reperfusion injury.

The application provides a traditional Chinese medicine composition resisting liver ischemia-reperfusion injury and application thereof, and belongs to the technical field of traditional Chinese medicine compositions; the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 1 part of liquorice, 1 part of salvia miltiorrhiza and 1 part of white peony root. In the application, the salvia miltiorrhiza has the effects of activating blood circulation to dissipate blood stasis, cooling blood to relieve pain and resisting oxidation; the white peony root can nourish blood and soothe liver (tonifying blood and nourishing liver) and inhibit inflammatory reaction; the liquorice has the functions of detoxification and regulating drug properties; the salvia miltiorrhiza, the white peony root and the liquorice have the effects of cooling blood to dissipate blood stasis, clearing heat to detoxify and tonifying blood to nourish liver in cooperation, and can effectively resist liver ischemia-reperfusion injury.

The invention relates to the field of regenerative medicine and tissue engineering, and provides application of a liver organoid in preparation of a medicine for treating liver ischemia reperfusion injury, the liver organoid realizes efficient transplantation and function integration of the organoid in an intraspleen injection mode, liver tissue injury caused by IRI is effectively improved, and the liver tissue injury is reduced. The repair and functional reconstruction of damaged tissues are promoted, the defects of the existing drug therapy and stem cell therapy are overcome, and a new path is developed for the treatment of liver diseases.

The invention relates to an application of a specific excitation Mas receptor in a medicine for preventing and treating hepatic ischemia-reperfusion injury. According to the invention, a G protein coupled receptor Mas coded by a protooncogene Mas1 is focused, a 70% warm ischemia reperfusion model of the liver is constructed by clamping left and middle leaf vessels of the liver by a vascular clamp after a mouse is laparotomy, and the condition that the liver injury can be obviously alleviated by activating the Mas receptor and the liver injury can be aggravated by knocking out the Mas receptor is fully proved on an in-vivo level; the invention provides an important early-stage data basis for research and development of new drugs based on specific activation of the Mas receptor, and is expected to provide an important animal experiment basis for development of new drugs aiming at the Mas receptor in a later stage.

The application discloses application of hsa_circ_0003258 in prevention and / or treatment of liver ischemia-reperfusion injury. The application is found by detection that the expression of hsa_circ_0003258 is significantly decreased in liver ischemia-reperfusion patients; overexpression of hsa_circ_0003258 can significantly inhibit macrophage inflammation and the apoptosis level of hepatocytes after hypoxia-reoxygenation treatment, and improve the function of hepatocytes; hsa_circ_0003258 has a protective effect on relieving liver ischemia-reperfusion injury, and has potential to become a drug for treating liver ischemia-reperfusion injury.

The invention belongs to the technical field of medical biology, and particularly relates to application of an ion channel in liver ischemia reperfusion injury aggravated by hypernatreemia. According to the application of the ion channel as a target for screening, preventing, relieving or / and treating the liver ischemia-reperfusion injury aggravated by the hypernatreemia, the ion channel is at least one of ENaC and NCX-1. Research finds that the hypernatremia aggravates ischemia reperfusion injury of the liver by activating an ENaC-NCX-1-NLRP3 signal channel, resulting in ROS increase, inflammation and aggravation of apoptosis, and the application of an inhibitor Amil of ENaC and an inhibitor SN-6 of NCX-1 can reduce the hypernatremia aggravated liver IRI, which brings a new therapeutic scheme for a donor of the hypernatremia, and has a broad application prospect. The improvement of the liver utilization rate of a hypernatremia donor is facilitated.

The application belongs to the field of biological medicine, and discloses application of echinocystic acid in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury. The application proves that the echinocystic acid significantly improves liver tissue injury, reduces serum ALT and AST levels, and reduces cell apoptosis through a mouse liver IRI model. It is found that the echinocystic acid activates the p38 MAPK signal pathway by inhibiting PTPN1, thereby activating Nrf2 and enhancing PINK1 / Parkin-mediated mitochondrial autophagy. In addition, the echinocystic acid promotes DRP1 phosphorylation and enhances the transfer of DRP1 to mitochondria, thereby reducing oxidative stress and inflammatory response. It is shown that the echinocystic acid regulates mitochondrial autophagy through the PTPN1 / p38 MAPK / Nrf2 pathway, has a significant liver protection effect, and provides a new idea for the treatment of IRI.